Benjamin Dryden on Government View of Merger Remedies – ‘No secret they are skeptical’
22 April 2024
Foley & Lardner LLP partner Benjamin Dryden assessed the U.S. Department of Justice’s and Federal Trade Commission’s increasingly aggressive scrutiny on mergers in the Law360 article, “What We’ve Learned From Biden-Era Merger Remedies.”
“They’ve made no secret of the fact that they are skeptical of merger remedies,” commented Dryden, who is vice-chair of Foley’s Antitrust & Competition Practice.
He explained that companies have realized that while government agencies are unlikely to accept offered remedies to address competition concerns, “a court might.” As a result, companies are potentially more willing to fight enforcers in court.
(Subscription required)
People
Related News
25 July 2024
In the News
Donald Schroeder on Groff – ‘Supreme Court decision is inviting a more fact-based analysis’
Foley & Lardner LLP partner Donald Schroeder assessed the impact of the U.S. Supreme Court’s 2023 decision in a religious accommodation case as it returns to the district court in the Law360 article, “A Year After High Court Spotlight, Groff Case Still A Bellwether.”
24 July 2024
In the News
Louis Lehot Featured in Q&A on How Startups Can Prepare for IPO
Foley & Lardner LLP partner Louis Lehot features in the Q&A, "How startups can get in top shape for an IPO, according to Silicon Valley lawyer Louis Lehot," part of Business Insider's Road to IPO' series.
24 July 2024
In the News
Courtenay Brinckerhoff on Patent Cap in Drug Pricing – ‘Hard to predict if this will make a difference’
Foley & Lardner LLP partner Courtenay Brinckerhoff discussed a recent bill passed in the U.S. Senate aimed at lowering drug prices by limiting the number of patents that can be asserted in cases over biosimilars in the Law360 article, “Patent Cap In Drug Pricing Bill Seen As Having Muted Effect.”